Serena Chew

Serena Chew

Auto-generated profile, based on publicly available information

Serena Chew

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
PDF file
SCSerena Chew
Serena Chew
MMMelissa C. Mackey
Melissa C. Mackey
EJElias Jabbour
Elias Jabbour
Acute myeloid leukemia (AML) is a malignancy of uncontrolled proliferation of immature myeloid blasts characterized by clonal evolution and genetic heterogeneity. FMS-like tyrosine kinase 3 (FLT3) mutations occur in up to a third of AML cases and are associated with highly proliferative disease, shorter duration of remission, and increased rates of disease relapse. The known impact of activating mutations in FLT3 in AML on disease pathogenesis, prognosis, and response to therapy has led to the development of tyrosine kinase inhibitors targeting FLT3. Gilteritinib is a potent, second generation inhibitor of both FLT3 and AXL, designed to address the limitations of other FLT3 inhibitors, particularly in targeting mechanisms of resistance to other drugs. In this review, we present comprehensive data on recent and ongoing studies evaluating the role of gilteritinib in the relapsed and refractory FLT3 mutated AML setting.

1 December 2020 in Best Practice & Research Clinical Haematology
Verified
Journal Article
Closed access
SCSerena Chew
Serena Chew
NJNadya Jammal
Nadya Jammal
HKHagop Kantarjian
Hagop Kantarjian
EJElias Jabbour
Elias Jabbour